(RTTNews) - Pfizer Inc. (PFE) Thursday said it has completed the licensing agreement with 3SBio, Inc. for exclusive rights to develop and sell 3SBio's SSGJ-707.
As per the deal, 3SBio will receive $1.25 billion, and Pfizer will also make a $100 million equity investment in 3SBio. Additionally, Pfizer gets the option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China. In return, Pfizer will pay up to $150 million in option payments.
SSGJ-707, developed using 3SBio's proprietary CLF2 platform, is currently in various clinical studies in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Positive interim results from the Phase 2 study of SSGJ-707 in patients with advanced NSCLC were recently reported.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
